Tim Williamson

• 
  phx.corporate-ir.net/phoenix.zhtml?c=92775&p=irol-govMa - [Cached Version]
  Published on: 9/3/2008    Last Visited: 9/3/2008  

  Tim WilliamsonChief Business Officer, Systems Medicine LLC
  
  Tim Williamson joined CTI's management team with our acquisition of Systems Medicine in July 2007.He is a founder of System Medicine and serves as its Chief Business Officer.Williamson's career spans 30+ years in large-cap pharma (Merck and Boehringer Mannheim), large-cap biotech (Genentech), start-up biotech (ILEX and DirectGene) and consulting.He has experience building the links and infrastructure necessary to bring innovative biotech products to market through his thorough understa...

• 
  www.celltherapeutics.com/leadership - [Cached Version]
  Published on: 9/3/2008    Last Visited: 9/3/2008  

  Tim Williamson Chief Business Officer, Systems Medicine
  ...
  Tim Williamson joined CTI's management team with our acquisition of Systems Medicine in July 2007.
  ...
  Mr. Williamson's career spans 30+ years in large-cap pharma (Merck and Boehringer Mannheim), large-cap biotech (Genentech), start-up biotech (ILEX and DirectGene) and consulting.He has experience building the links and infrastructure necessary to bring innovative biotech products to market through his thorough understanding of pharmaceutical company needs and capabilities, including experience marketing new products, negotiating international product licensing agreements, building sales and marketing organizations, and building a successful start-up company from scratch (i.e., ILEX Oncology where he was one of the first three employees).
  
  Mr. Williamson has played key roles in the development and launch of such products as Merck's first recombinant vaccine, Genentech's recombinant human growth hormone (rHGH) and recombinant tissue plasminogen activator (rTPA), and ILEX's humanized monoclonal antibody, CAMPATH.Prior to joining Systems Medicine, Williamson negotiated numerous product deals and alliances including ILEX's agreement giving Schering AG worldwide distribution rights to CAMPATH in return for $30.0 million in fees and milestones, 60% of the profit in the U.S. and a royalty comparable to 60% profit in the rest of the territory (The Pink Sheet, 08/30/99, p. 21).

• 
  www.ithacajournal.com/apps/pbcs.dll/article?AID=/200704 - [Cached Version]
  Published on: 4/28/2007    Last Visited: 4/28/2007  

  Systems Medicine principals Timothy Williamson, chief business officer; Jeff Jacob, president and CEO; and Spyro Mousses, chief scientific officer, stand together at their Scottsdale, Ariz., offices.

• 
  Cell Therapeutics Corporate Governance - Biography - [Cached Version]
  Published on: 5/18/2008    Last Visited: 5/18/2008  

  Tim WilliamsonCell Therapeutics Corporate Governance - Biography
  ...
  Tim WilliamsonChief Business Officer, Systems Medicine LLC
  
  Tim Williamson joined CTI's management team with our acquisition of Systems Medicine in July 2007.He is a founder of System Medicine and serves as its Chief Business Officer.Williamson's career spans 30+ years in large-cap pharma (Merck and Boehringer Mannheim), large-cap biotech (Genentech), start-up biotech (ILEX and DirectGene) and consulting.He has experience building the links and infrastructure necessary to bring innovative biotech products to market through his thorough understanding of pharmaceutical company needs and capabilities, including experience marketing new products, negotiating international product licensing agreements, building sales and marketing organizations, and building a successful start-up company from scratch (i.e., ILEX Oncology where he was one of the first three employees).
  
  Williamson has played key roles in the development and launch of such products as Merck's first recombinant vaccine, Genentech's recombinant human growth hormone (rHGH) and recombinant tissue plasminogen activator (rTPA), and ILEX's humanized monoclonal antibody, CAMPATH.Prior to joining Systems Medicine, Williamson negotiated numerous product deals and alliances including ILEX's agreement giving Schering AG worldwide distribution rights to CAMPATH in return for $30.0 million in fees and milestones, 60% of the profit in the U.S. and a royalty comparable to 60% profit in the rest of the territory (The Pink Sheet, 08/30/99, p. 21).

• 
  Cell Therapeutics Corporate Governance - Board of... - [Cached Version]
  Published on: 5/18/2008    Last Visited: 5/18/2008  

  Tim WilliamsonChief Business Officer, Systems Medicine LLC

• 
  Cell Therapeutics News Release - [Cached Version]
  Published on: 7/25/2007    Last Visited: 12/11/2007  

  Timothy Williamson is CBO and a founder of SMI.

• 
  Cell Therapeutics cancer drug development and research... - [Cached Version]
  Published on: 8/4/2008    Last Visited: 8/4/2008  

  Tim Williamson Chief Business Officer, Systems Medicine
  ...
  Tim Williamson joined CTI's management team with our acquisition of Systems Medicine in July 2007.
  ...
  Williamson has played key roles in the development and launch of such products as Merck's first recombinant vaccine, Genentech's recombinant human growth hormone (rHGH) and recombinant tissue plasminogen activator (rTPA), and ILEX's humanized monoclonal antibody, CAMPATH.Prior to joining Systems Medicine, Williamson negotiated numerous product deals and alliances including ILEX's agreement giving Schering AG worldwide distribution rights to CAMPATH in return for $30.0 million in fees and milestones, 60% of the profit in the U.S. and a royalty comparable to 60% profit in the rest of the territory (The Pink Sheet, 08/30/99, p. 21).

• 
  Dotcom exiles turn up at new charities | csmonitor.com - [Cached Version]
  Last Visited: 6/24/2003  

  "We started this as a for-profit entity and raised over $1 million," says Timothy Williamson, its founder."But we quickly realized there were a number of advantages to being a nonprofit, including access to community funding," he says.
  
  That's where he may run into trouble.Lack of understanding the financial-management issues is the No. 1 shortcoming for technology executives entering the nonprofit world, according to the Management Center's O'Grady.
  
  "Understanding tax laws and fundraising regulations is ... where many are coming up short," he says.

• 
  Investors - Cell Therapeutics, Inc. - Biography - [Cached Version]
  Published on: 9/3/2008    Last Visited: 9/3/2008  

  Tim WilliamsonChief Business Officer, Systems Medicine LLC
  
  Tim Williamson joined CTI's management team with our acquisition of Systems Medicine in July 2007.He is a founder of System Medicine and serves as its Chief Business Officer.Williamson's career spans 30+ years in large-cap pharma (Merck and Boehringer Mannheim), large-cap biotech (Genentech), start-up biotech (ILEX and DirectGene) and consulting.He has experience building the links and infrastructure necessary to bring innovative biotech products to market through his thorough understanding of pharmaceutical company needs and capabilities, including experience marketing new products, negotiating international product licensing agreements, building sales and marketing organizations, and building a successful start-up company from scratch (i.e., ILEX Oncology where he was one of the first three employees).
  
  Williamson has played key roles in the development and launch of such products as Merck's first recombinant vaccine, Genentech's recombinant human growth hormone (rHGH) and recombinant tissue plasminogen activator (rTPA), and ILEX's humanized monoclonal antibody, CAMPATH.Prior to joining Systems Medicine, Williamson negotiated numerous product deals and alliances including ILEX's agreement giving Schering AG worldwide distribution rights to CAMPATH in return for $30.0 million in fees and milestones, 60% of the profit in the U.S. and a royalty comparable to 60% profit in the rest of the territory (The Pink Sheet, 08/30/99, p. 21).

• 
  Systems Medicine Inc. - [Cached Version]
  Published on: 7/3/2008    Last Visited: 7/3/2008  

  Timothy J. Williamson - Chief Business Officer and Founder
  ...
  Tim WilliamsonCBO & Founder
  ...
  Tim's career spans 30+ years in large-cap pharma (Merck and Boehringer Mannheim), large-cap biotech (Genentech), start-up biotech (ILEX and DirectGene) and consulting.Tim has experience building the links and infrastructure necessary to bring innovative biotech products to market through his thorough understanding of pharmaceutical company needs and capabilities, including experience marketing new products, negotiating international product licensing agreements, building sales and marketing organizations and building a successful start-up company from scratch (i.e., ILEX Oncology where he was one of the first three employees).
  
  Tim has played key roles in the development and launch of such products as Merck's first recombinant vaccine, Genentech's recombinant human growth hormone (rHGH) and recombinant tissue plasminogen activator (rTPA), and ILEX's humanized monoclonal antibody, CAMPATH.Prior to joining SMi, Tim negotiated numerous product deals and alliances including ILEX's agreement giving Schering AG worldwide distribution rights to CAMPATH in return for $30.0 million in fees and milestones, 60% of the profit in the U.S. and a royalty comparable to 60% profit in the rest of the territory (The Pink Sheet, 08/30/99, p. 21).

Page:  1 2